{"id":"lnk01001","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While specific mechanistic details for LNK01001 are limited in public literature, it is being developed by Lynk Pharmaceuticals as an immunotherapy candidate in Phase 3 development. The drug likely modulates immune checkpoint signaling to reinvigorate T-cell mediated anti-tumor responses, though the precise molecular target requires confirmation from clinical trial data.","oneSentence":"LNK01001 is an investigational therapeutic targeting immune checkpoint pathways to enhance anti-tumor immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:19:15.191Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication under Phase 3 evaluation)"}]},"trialDetails":[{"nctId":"NCT06276998","phase":"PHASE3","title":"A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lynk Pharmaceuticals Co., Ltd","startDate":"2023-12-12","conditions":"Rheumatoid Arthritis","enrollment":430},{"nctId":"NCT07237568","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis","status":"RECRUITING","sponsor":"Lynk Pharmaceuticals Co., Ltd","startDate":"2025-08-29","conditions":"Ankylosing Spondylitis","enrollment":352},{"nctId":"NCT06277245","phase":"PHASE3","title":"A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lynk Pharmaceuticals Co., Ltd","startDate":"2024-02-06","conditions":"Atopic Dermatitis","enrollment":354},{"nctId":"NCT06085534","phase":"PHASE2","title":"A Study of LNK01001 Capsule in Patients With Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Lynk Pharmaceuticals Co., Ltd","startDate":"2022-01-06","conditions":"Ankylosing Spondylitis","enrollment":177},{"nctId":"NCT06085521","phase":"PHASE2","title":"A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Lynk Pharmaceuticals Co., Ltd","startDate":"2022-01-26","conditions":"Atopic Dermatitis","enrollment":150},{"nctId":"NCT06099535","phase":"PHASE2","title":"A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Lynk Pharmaceuticals Co., Ltd","startDate":"2021-11-18","conditions":"Rheumatoid Arthritis","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LNK01001","genericName":"LNK01001","companyName":"Lynk Pharmaceuticals Co., Ltd","companyId":"lynk-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LNK01001 is an investigational therapeutic targeting immune checkpoint pathways to enhance anti-tumor immunity. Used for Cancer (specific indication under Phase 3 evaluation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}